Showing results (51-60 of 62) with videos related to

Sort By:
Pageof 7
Experimental and Molecular Pathology|October 9, 2007
Deficiency in monocyte chemoattractant protein-1 modifies lipid and glucose metabolismAnna Rull, Joan Carles Escolà-Gil, Josep Julve, et al.
Clinical Chemistry and Laboratory Medicine|May 9, 2007
Association of a polymorphism in the promoter of the cellular retinoic acid-binding protein II gene (CRABP2) with increased circulating low-density lipoprotein cholesterolJuliana Salazar, Montse Guardiola, Raimon Ferré, et al.
European Journal of Pharmacology|July 18, 2006
Effects of rosiglitazone and metformin on postprandial paraoxonase-1 and monocyte chemoattractant protein-1 in human immunodeficiency virus-infected patients with lipodystrophyBlai Coll, Jeroen P H van Wijk, Sandra Parra, et al.
European Journal of Echocardiography : the Journal of the Working Group on Echocardiography of the European Society of Cardiology|April 14, 2010
Contrast-enhanced ultrasound for imaging vasa vasorum: comparison with histopathology in a swine model of atherosclerosisArend F L Schinkel, Chris G Krueger, Armando Tellez, et al.
JACC. Cardiovascular Imaging|July 17, 2010
Contrast-enhanced ultrasound imaging of the vasa vasorum: from early atherosclerosis to the identification of unstable plaquesDaniel Staub, Arend F L Schinkel, Blai Coll, et al.
Clinical Journal of the American Society of Nephrology : CJASN|July 9, 2015
Predictors of Atrasentan-Associated Fluid Retention and Change in Albuminuria in Patients with Diabetic NephropathyDonald E Kohan, Hiddo J Lambers Heerspink, Blai Coll, et al.
Journal of the American Society of Nephrology : JASN|April 12, 2014
The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathyDick de Zeeuw, Blai Coll, Dennis Andress, et al.
Diabetes, Obesity & Metabolism|December 17, 2016
Comparison of exposure response relationship of atrasentan between North American and Asian populationsHiddo J L Heerspink, Hirofumi Makino, Dennis Andress, et al.
Nature Medicine|June 5, 2026
Oral small molecule GLP-1 receptor agonist aleniglipron in people with overweight or obesity: a randomized, double-blind, placebo-controlled phase 2b trialJulio Rosenstock, Ildiko Lingvay, Donna Ryan, et al.
Diabetes, Obesity & Metabolism|December 27, 2016
The effects of atrasentan on urinary metabolites in patients with type 2 diabetes and nephropathyMichelle J Pena, Dick de Zeeuw, Dennis Andress, et al.
Pageof 7